Trajectories of Blood Pressure in Midlife Women: Does Menopause Matter?

arterial pressure blood pressure estradiol follicle stimulating hormone follow-up studies hot flashes menopause

Journal

Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103

Informations de publication

Date de publication:
04 02 2022
Historique:
entrez: 3 2 2022
pubmed: 4 2 2022
medline: 25 2 2022
Statut: ppublish

Résumé

Whether changes in blood pressure (BP) over women's midlife are more driven by chronological aging or the menopause transition has been debated. We sought to determine whether women can be classified into distinct trajectory groups based on pattern and level of systolic BP (SBP), diastolic BP, pulse pressure (PP), and mean arterial pressure (MAP) over the menopause transition, and to assess whether menopause-related factors predict the group and level of BP measures. Participants were from the SWAN (Study of Women's Health Across the Nation). Group-based trajectory modeling was used to identify women who shared distinct BP trajectories over time relative to menopause onset and to assess associations of menopause-related factors with trajectory group and level of BP measures. An accelerated rise relative to menopause onset suggests a menopause contribution. The study included 3302 multiracial and multiethnic women with BP measures over 17 follow-up visits (baseline age [SD]: 46.3 [2.7]). Women were classified into either low, medium, or high trajectory group in each BP measure. The low SBP, PP, and MAP trajectories (in 35%, 53%, and 28% of the cohort, respectively) were rising slowly before menopause but showed a significant accelerated rise 1 year after menopause, indicating a menopause contribution. The remaining BP trajectories were rising up until menopause and either continued with the same rise or declined after menopause. A younger menopause age predicted the low SBP, PP, and MAP trajectories. A greater follicle-stimulating hormone level predicted lower SBP and PP levels, while vasomotor symptoms occurrence predicted higher SBP, PP, and MAP levels over time. Estradiol did not predict trajectory or level of any BP measure. Distinct BP trajectories over the menopause transition exist that revealed a group of women whose SBP, PP, and MAP trajectories are consistent with a menopause contribution. Our findings support frequent monitoring of BP during the menopause transition.

Sections du résumé

BACKGROUND
Whether changes in blood pressure (BP) over women's midlife are more driven by chronological aging or the menopause transition has been debated. We sought to determine whether women can be classified into distinct trajectory groups based on pattern and level of systolic BP (SBP), diastolic BP, pulse pressure (PP), and mean arterial pressure (MAP) over the menopause transition, and to assess whether menopause-related factors predict the group and level of BP measures.
METHODS
Participants were from the SWAN (Study of Women's Health Across the Nation). Group-based trajectory modeling was used to identify women who shared distinct BP trajectories over time relative to menopause onset and to assess associations of menopause-related factors with trajectory group and level of BP measures. An accelerated rise relative to menopause onset suggests a menopause contribution.
RESULTS
The study included 3302 multiracial and multiethnic women with BP measures over 17 follow-up visits (baseline age [SD]: 46.3 [2.7]). Women were classified into either low, medium, or high trajectory group in each BP measure. The low SBP, PP, and MAP trajectories (in 35%, 53%, and 28% of the cohort, respectively) were rising slowly before menopause but showed a significant accelerated rise 1 year after menopause, indicating a menopause contribution. The remaining BP trajectories were rising up until menopause and either continued with the same rise or declined after menopause. A younger menopause age predicted the low SBP, PP, and MAP trajectories. A greater follicle-stimulating hormone level predicted lower SBP and PP levels, while vasomotor symptoms occurrence predicted higher SBP, PP, and MAP levels over time. Estradiol did not predict trajectory or level of any BP measure.
CONCLUSIONS
Distinct BP trajectories over the menopause transition exist that revealed a group of women whose SBP, PP, and MAP trajectories are consistent with a menopause contribution. Our findings support frequent monitoring of BP during the menopause transition.

Identifiants

pubmed: 35113663
doi: 10.1161/CIRCRESAHA.121.319424
pmc: PMC8814466
mid: NIHMS1767463
doi:

Substances chimiques

Estradiol 4TI98Z838E
Follicle Stimulating Hormone 9002-68-0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

312-322

Subventions

Organisme : NIA NIH HHS
ID : R01 AG062622
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012554
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024131
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012505
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012531
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL123565
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012535
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012553
Pays : United States
Organisme : NINR NIH HHS
ID : U01 NR004061
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012539
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012546
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG063720
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012495
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

J Hypertens. 2000 Jan;18(1):27-33
pubmed: 10678540
JAMA Cardiol. 2020 Mar 1;5(3):19-26
pubmed: 31940010
Circulation. 2020 Dec 22;142(25):e506-e532
pubmed: 33251828
J Lipid Res. 2012 May;53(5):909-917
pubmed: 22345708
BMC Med. 2017 Jan 4;15(1):2
pubmed: 28049531
Circulation. 2018 Jun 12;137(24):e843-e852
pubmed: 29748185
Maturitas. 2015 Mar;80(3):282-7
pubmed: 25563399
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
Arterioscler Thromb Vasc Biol. 2020 Apr;40(4):1001-1008
pubmed: 31969013
JAMA Intern Med. 2018 Jan 1;178(1):93-99
pubmed: 29204655
Int J Epidemiol. 1990 Mar;19(1):42-8
pubmed: 2351523
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
J Atheroscler Thromb. 2013;20(2):161-9
pubmed: 23079582
J Womens Health (Larchmt). 2016 Dec;25(12):1204-1209
pubmed: 27404767
Heart. 2016 Dec 1;102(23):1898-1901
pubmed: 27354275
Trends Endocrinol Metab. 2009 Oct;20(8):374-9
pubmed: 19734053
Hypertension. 2009 Jul;54(1):11-8
pubmed: 19470884
Am J Hypertens. 2007 Oct;20(10):1045-50
pubmed: 17903686
BJOG. 2005 Apr;112(4):476-85
pubmed: 15777448
Menopause. 2014 Jun;21(6):624-32
pubmed: 24149926
N Engl J Med. 1989 Sep 7;321(10):641-6
pubmed: 2488072
Am J Hypertens. 2009 Nov;22(11):1148-53
pubmed: 19713943
Hypertension. 1995 Mar;25(3):305-13
pubmed: 7875754
Ann Epidemiol. 1998 Jan;8(1):39-45
pubmed: 9465992
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
BMC Womens Health. 2015 Aug 22;15:64
pubmed: 26296869
Maturitas. 2004 Feb 20;47(2):131-8
pubmed: 14757272
J Am Coll Cardiol. 2009 Dec 15;54(25):2366-73
pubmed: 20082925
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Fertil Steril. 1998 Aug;70(2):332-7
pubmed: 9696230
Atherosclerosis. 2001 May;156(1):157-63
pubmed: 11369009
Hypertension. 2008 Apr;51(4):952-9
pubmed: 18259027
Circulation. 2021 Feb 16;143(7):761-763
pubmed: 33587655
Curr Hypertens Rep. 2006 Oct;8(5):368-76
pubmed: 16965722
Atherosclerosis. 1999 Feb;142(2):415-23
pubmed: 10030394
J Am Heart Assoc. 2017 Aug 30;6(9):
pubmed: 28855169
Biol Reprod. 2014 Sep;91(3):74
pubmed: 25100706
Atherosclerosis. 2012 Sep;224(1):228-34
pubmed: 22862963
Menopause. 2016 Oct;23(10):1067-74
pubmed: 27404029
Am J Med. 2005 Dec 19;118 Suppl 12B:14-24
pubmed: 16414323
Am J Transl Res. 2020 Jul 15;12(7):3116-3132
pubmed: 32774689
Lancet. 2014 May 31;383(9932):1899-911
pubmed: 24881994
J Clin Endocrinol Metab. 2012 Aug;97(8):2872-80
pubmed: 22659249
Eur J Prev Cardiol. 2016 May;23(7):694-703
pubmed: 26385249
Stat Med. 2005 Oct 15;24(19):2911-35
pubmed: 16152135
JAMA Cardiol. 2020 Sep 1;5(9):1011-1018
pubmed: 32936272
J Clin Endocrinol Metab. 2016 Jan;101(1):254-63
pubmed: 26583582

Auteurs

Saad Samargandy (S)

Department of Community Medicine, King Abdulaziz University, Jeddah, Saudi Arabia (S.S.).

Karen A Matthews (KA)

Department of Psychiatry (K.A.M.), University of Pittsburgh, PA.

Maria M Brooks (MM)

Graduate School of Public Health (M.M.B., E.B.-M., R.C.T., S.R.E.), University of Pittsburgh, PA.

Emma Barinas-Mitchell (E)

Graduate School of Public Health (M.M.B., E.B.-M., R.C.T., S.R.E.), University of Pittsburgh, PA.

Jared W Magnani (JW)

Department of Medicine (J.W.M.), University of Pittsburgh, PA.

Rebecca C Thurston (RC)

Graduate School of Public Health (M.M.B., E.B.-M., R.C.T., S.R.E.), University of Pittsburgh, PA.

Samar R El Khoudary (SR)

Graduate School of Public Health (M.M.B., E.B.-M., R.C.T., S.R.E.), University of Pittsburgh, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH